KALA BIO, Inc. (KALA) Stock Price, Quote & News - Stock Analysis (2024)

KALA BIO to Present at Jefferies Global Healthcare Conference KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update KALA BIO to Participate in Upcoming Investor Conferences in August Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA) Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors Kala Pharmaceuticals Announces Reverse Stock Split References